AstraZeneca logo

AZN - AstraZeneca News Story

7943p -12.0  -0.2%

Last Trade - 23/10/20

Sector
Healthcare
Size
Large Cap
Market Cap £104.24bn
Enterprise Value £115.78bn
Revenue £19.71bn
Position in Universe 7th / 1805

BRIEF-AstraZeneca Says Lynparza Improved Median Time Patients Lived Without Disease Progression In BRCA-Mutated Advanced Ovarian Cancer

Fri 18th September, 2020 8:07am
Sept 18 (Reuters) - AstraZeneca PLC  AZN.L :
    * ASTRAZENECA-LYNPARZA IMPROVED MEDIAN TIME PATIENTS LIVED
WITHOUT
DISEASE PROGRESSION TO OVER 4 & HALF YRS IN BRCA-MUTATED
ADVANCED OVARIAN CANCER


Further company coverage:  AZN.L 

 ((Reuters.Briefs@thomsonreuters.com;))
© Stockopedia 2020, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.